NCT02090465

Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks

Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate (Picato) in a Period of 8 Weeks.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 840 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Assessment of treatment success and quality of life in patients with actinic keratoses under therapy with Ingenol Mebutate (Picato) in a period of 8 weeks.

Detailed description

Non-interventional (observational) study (NIS), non-controlled, prospective cohort study.

Conditions

• Actinic Keratosis

Interventions

Type	Name	Description
DRUG	Ingenol Mebutate	No intervention: observation of routine use of Picato®

Timeline

• Start date: 2013-07-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2014-03-18
• Last updated: 2019-12-17

Locations

1 site across 1 country: Germany